iRhythm Q3 2023 revenue $124.6M (+20% YoY); raises FY2023 guidance to $487.5M-$490M

iRhythm Holdings, Inc.

2023-Q3 EPS reported -$2.78 revenue$360,170,000

Revenue $124.6M (+20% YoY); net loss $27.1M ($0.89/share) vs $21.5M loss in prior year.
Gross margin 66.2%, down 210 bps due to reserves for excess Zio XT PCBA components.
Record registration volumes; launched next-generation Zio monitor with enhanced features.
FY2023 revenue guidance raised to $487.5M-$490M (~19% YoY growth); adj. EBITDA margin ~0%-0.5%.
Cash and marketable securities $158.5M as of Sept 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

iRhythm Holdings, Inc. reported for the three and nine months ended September 30, 2023 results: revenue $124.6 million, net income $27.1 million, EPS $0.89 per share. Guidance raised.

Period: for the three and nine months ended September 30, 2023
Revenue: $124.6 million
Net income: $27.1 million
EPS: $0.89 per share
Guidance: raised
Result: reported results

Exact text from the filing

iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three and nine months ended September 30, 2023. Third Quarter 2023 Financial Highlights • Revenue of $124.6 million, a 20.0% increase compared to third quarter 2022

View on SEC.gov

Browse all earnings releases →

iRhythm Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001388658-23-000145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.